Benkert O, Laakmann G, Ott L, Strauss A, Zimmer R
Arzneimittelforschung. 1977;27(12):2421-3.
Z-1-(4-Bromophenyl)-1-(3-pyridyl)-3-dimethylaminopropene dihydrochloride hydrate (zimelidine; H 102/09), a newly developed bicyclic substance, was tested in a pilot study for its clinical effect in 10 female patients with a depressive syndrome. Zimelidine inhibits the 5-hydroxytryptamine (5-HT) reuptake more potently than does chlorimipramine. The action on the norepinephrine reuptake is weaker compared with imipramine, also the cardiotoxic and anticholinergic effects are lower. Zimelidine was administered for 20 days in a daily dose of 150 mg. A significant (p less than 0.05) improvement from the beginning of the treatment to the 15th day was demonstrated in Hamilton rating scale and a self-rating scale (von Zerssen). Nevertheless, the zimelidine treatment had to be discontinued between the 15th and 18th days in 3 patients, because of agitation symptoms. The antidepressant action in some patients justifies the performance of controlled studies.
Z-1-(4-溴苯基)-1-(3-吡啶基)-3-二甲氨基丙烯二盐酸盐水合物（齐美利定；H 102/09）是一种新开发的双环物质，在一项初步研究中对10名患有抑郁综合征的女性患者进行了临床疗效测试。齐美利定抑制5-羟色胺（5-HT）再摄取的能力比氯米帕明更强。与丙咪嗪相比，其对去甲肾上腺素再摄取的作用较弱，心脏毒性和抗胆碱能作用也较低。齐美利定以每日150毫克的剂量给药20天。汉密尔顿评定量表和自评量表（冯·泽尔森）显示，从治疗开始到第15天有显著（p<0.05）改善。然而，3名患者在第15天至18天之间因出现激动症状而不得不停止齐美利定治疗。一些患者的抗抑郁作用证明有必要进行对照研究。
